4 news items
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
ATXI
FBIO
16 May 24
alternatives for our targeted indications; the possibility that the government or third-party payors fail to provide adequate coverage and payment rates for our
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI
FBIO
15 May 24
products to emerge that provide different or better therapeutic alternatives for our targeted indications; the possibility that the government or third
Avenue Therapeutics Announces Reverse Stock Split
ATXI
FBIO
24 Apr 24
products to emerge that provide different or better therapeutic alternatives for our targeted indications; the possibility that the government or third
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
ATXI
FBIO
18 Mar 24
for our targeted indications; the possibility that the government or third-party payors fail to provide adequate coverage and payment rates for our product
- Prev
- 1
- Next